GlassScriptPhysician profile
Bryan S Calcote
NPI 1073622999
$5,866.91
in general payments reported to CMS, 2019-2025
34 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $1,125 · 2021: $1,060 · 2022: $1,063 · 2023: $692 · 2024: $584 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $718.29 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $659.56 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $568.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $543.19 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $439.10 | 2019-2025 | |
| Amgen INC. | $430.36 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $380.04 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $324.28 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.40 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $250.72 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.80 | 2019-2022 | |
| Abbvie INC. | $193.52 | 2020-2025 | Ubrelvy |
| Allergan, INC. | $115.62 | 2020 | |
| Corcept Therapeutics | $99.83 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $79.19 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $69.05 | 2021-2022 | |
| Abbott Laboratories | $66.63 | 2022-2024 | Freestyle Libre |
| Glaxosmithkline, LLC. | $57.46 | 2019-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $52.17 | 2019-2023 | Veozah |
| Esperion Therapeutics, INC. | $48.42 | 2021 | |
| Currax Pharmaceuticals LLC | $44.92 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $43.16 | 2022-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $33.08 | 2025 | Zoryve |
| Exact Sciences Corporation | $32.04 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $19.54 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $17.65 | 2020 | |
| Reprise Biomedical, INC. | $17.30 | 2025 | Miro3d |
| Fidia Pharma USA INC. | $16.97 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $16.63 | 2023 | Voquezna |
| Nestle Healthcare Nutrition INC. | $16.21 | 2020 | |
| Hikma Pharmaceuticals USA | $12.91 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.77 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.48 | 2019 | |
| Amarin Pharma, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Calcote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.